Aztreonam lysine for inhalation solution: In cystic fibrosis

Drugs

Volumn 70, Issue 14, 2010, Pages 1843-1855

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Aztreonam, general; Cystic fibrosis; Inhalation; Pseudomonal infections

Indexed keywords

ARGININE; AZETIDINE DERIVATIVE; AZTREONAM; AZTREONAM LYSINE; BRONCHODILATING AGENT; CAYSTON; COLISTIN; MONOBACTAM DERIVATIVE; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; FEVER; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; INJECTION; LARYNX PAIN; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEBULIZER; NOSE CONGESTION; PATIENT COMPLIANCE; PRESCRIPTION; PSEUDOMONAS INFECTION; REVIEW; SPUTUM CULTURE; SURVIVAL; TISSUE INJURY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WHEEZING;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; AZTREONAM; CYSTIC FIBROSIS; HUMANS; LYSINE; PHARMACEUTICAL SOLUTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 77956571065     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10484070-000000000-00000     Document Type: Review

References (48)

1. Davis PB, Drumm M, Konstan MW. State of the art: cystic fibrosis. Am J Respir Crit Care Med 1996; 154 (5): 1229-1256
2. Cystic Fibrosis Foundation. Patient registry: annual data report 2008. Bethesda (MD): Cystic Fibrosis Foundation, 2009
3. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007 Nov 15; 176 (10): 957-969
4. Cystic Fibrosis Foundation. About cystic fibrosis [online]. Available from URL: http://www.cff.org/AboutCF/[Accessed 2010 Jul 16]
5. Cystic Fibrosis Foundation. About cystic fibrosis-frequently asked questions [online]. Available from URL: http://www.cff.org/AboutCF/Faqs/ [Accessed 2010 Jul 16]
6. UK CF Registry Annual Data Report 2008 [online]. Avail-able from URL: http://www.cftrust.org.uk/aboutcf/publi cations/cfregistryreports/UK-CF- Registry-Annual-Data- Report-2008.pdf [Accessed 2010 Aug 9]
7. Hodson ME, Penketh AR, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981 Nov 21; 2 (8256): 1137-1139
8. Wall MA, Terry AB, Eisenberg J, et al. Inhaled antibiotics in cystic fibrosis [letter]. Lancet 1983 Jun 11; 1 (8337): 1325
9. Littlewood JM, Miller MG, Ghoneim AT, et al. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis [letter]. Lancet 1985 Apr 13; 1 (8433): 865
10. Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987 Jun; 19 (6): 831-838
11. Hodson ME. Antibiotic treatment: aerosol therapy. Chest 1988 Aug; 94 (2 Suppl): 156S-62S
12. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent ad-ministration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999 Jan 7; 340 (1): 23-30
13. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993 Jun 17; 328 (24): 1740-1746
14. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001 Sep; 120 (3 Suppl): 107S-13S
15. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002 Sep; 20 (3): 658-664
16. Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, et al. Nebulized antibiotics in cystic fibrosis. Pediatric Drugs 2002; 4 (7): 455-467
17. Tiddens H. Inhaled antibiotics. Pediatr Pulmonol 2004; 26 Suppl.: 92-94
18. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009 May; 54 (5): 658-670
19. Garcia-Contreras L, Hickey AJ. Aerosol treatment of cystic fibrosis. Crit Rev Ther Drug Carrier Syst 2003; 20 (5): 317-356
20. Novartis. TOBI® (Tobramycin inhalation solution, USP) [online]. Available from URL: http://www.pharma.us.novartis. com/product/pi/pdf/tobi.pdf [Accessed 2010 Aug 12]
21. Novartis Pharmaceuticals UK Ltd. Tobi® (tobramycin 300mg/5mL nebuliser solution): summary of product characteristics [online]. Available from URL: http://www.medi cines.org.uk/emc/medicine/19020/spc/[Accessed 2010 Aug 12]
22. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI®): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63 (22): 2501-2520
23. Fernandez JD, Santiago RT, Matacon MP, et al. Inhaled aztreonam therapy in patients with cystic fibrosis colonized with "Pseudomonas aeruginosa" [in Spanish]. An Esp Pediatr 1994; 40 (3): 185-188
24. Bristol-Myers Squibb. Azactam® (aztreonam for injection, USP) [online]. Available from URL: http://packageinserts. bms.com/pi/pi-azactam.pdf [Accessed 2010 Jul 22]
25. Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Micro-biology, safety, and pharmacokinetics of aztreonam lysi-nate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006 Jul; 41 (7): 656-665
26. Brewer NS, Hellinger WC. The monobactams. Mayo Clin Proc 1991; 66: 1152-1157
27. Mulligan MS, Hevel JM, Marletta MA, et al. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 1991 Jul 15; 88 (14): 6338-6342
28. Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine im-proves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 208-212
29. Dietzsch HJ, Gottschalk B, Heyne K, et al. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975 Jan; 55 (1): 96-100
30. Cayston® (aztreonam for inhalation solution): US prescrib-ing information. Foster City (CA): Gilead Sciences, Inc., 2010 Feb
31. European Medicines Agency. Aztreonam lysine (Cayston®) powder and solvent for nebuliser solution: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2010 Jul 16]
32. McCoy K, Retsch-Bogart G, Gibson RL, et al. Microbio-logic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) [poster no. 142]. 31st European Cystic Fibrosis Conference; 2008 Jun 11-14; Prague
33. McCoy K, Retsch-Bogart G, Gibson RL, et al. Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis [poster no. 418]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23-25; Orlando (FL)
34. Oermann CM, McCoy K, Retsch-Bogart G, et al. Antibiotic susceptibility of P. aeruginosa isolates following repeated exposure to aztreonam for inhalation solution in patients with cystic fibrosis [poster no. 278]. 23rd Annual North American Cystic Fibrosis Conference; 2009 Oct 15-17; Minneapolis (MN)
35. Perry JD, Laine L, Hughes S, et al. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J Antimicrob Chemother 2008 Mar 3; 61: 1057-1061
36. Burns JL, Griffith A. Pseudomonas aeruginosa killing cur-ves for aztreonam in the presence of cystic fibrosis sputum or porcine gastric mucin [poster no. 332]. 17th Annual North American Cystic Fibrosis Conference; 2003 Oct 16-19; Anaheim (CA)
37. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-1232
38. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-928
39. Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008 Jan; 43 (1): 47-58
40. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. Epub 2010 Jul 29
41. Wainwright C, Nakamura C, Geller DE, et al. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA) [abstract no. 81 plus poster]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16-19; Valencia
42. Assael BM, La Rosa M, Knoop C, et al. Aztreonam for inhalation solution (AZLI) head to head trial, a comparative trial vs. tobramycin nebuliser solution (TNS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (PA): results of first treatment cycle [abstract plus oral presentation]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16-19; Valencia
43. PARI Pharma's Altera delivers Gilead's Cayston in head-to-head study with torbramycin inhalation solution [media release]. 2010 Jun 21 [online]. Available from URL http://www.drugs.com/clinical-trials/pari-pharma-s-altera- delivers-gilead-s-cayston-head-head-study-tobramycin-inhalation-solution-9674. html
44. PARI Pharma's Altera delivers Gilead's Cayston in head-to-head study with torbramycin inhalation solution [media release]. 2010 Jun 21 [online]. Available from URL http://www.drugs.com/clinical-trials/pari-pharma-s-altera- delivers-gilead-s-cayston-head-head-study-tobramycin-inhalation-solution-9674. html
45. American Thoracic Society. Cystic Fibrosis Questionnaire (CFQ); Cystic Fibrosis Questionnaire Revised (CFQ-R) [online]. Available from URL: http://qol.thoracic.org/sec tions/instruments/ae/pages/cfq-cfq-r.html [Accessed 2010 Jul 22]
46. Quittner AL, McCoy KS, Montgomery AB. Inhaled antibiotics to treat stable patients with cystic fibrosis and pseudomonas aeruginosa (PA): measuring patient perception of symptom improvement [poster no. 280]. 21st Annual North American Cystic Fibrosis Conference; 2007 Oct 3-6; Anaheim (CA)
47. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnarie-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135: 1610-1618
48. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001 Sep; 139 (3): 359-65